SCHEMBL2213308

SCHEMBL2213308

Nc1ccc(C(=O)Nc2ccc(Nc3nc(-c4cccc(Br)c4)cc4ccnn34)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPL P40238 1/20 0.43
POLB P06746 5/20 0.43
MAPT P10636 5/20 0.43
ABL1 P00519 2/20 0.41
BCR P11274 2/20 0.41
ABL2 P42684 1/20 0.41
CSNK2A2 P19784 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A1 P68400 1/20 0.41
CSNK2A3 Q8NEV1 1/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
LMNA P02545 2/20 0.40
PKM P14618 1/20 0.40
APEX1 P27695 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
DNMT1 P26358 1/20 0.39
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2216196 0.90 PRMT1 (0.45) POLBMAPTABL1BCRABL2
SCHEMBL2214248 0.83 ABL1 (0.50) ABL1BCRABL2CSNK2A2LMNA
SCHEMBL2214589 0.81 HDAC1 (0.45) POLBMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2215396 0.80 NPC1 (0.39) POLBMAPTKMT2AMEN1NPC1
SCHEMBL2211981 0.80 HDAC1 (0.45) POLBMAPTKMT2AMEN1SMN1; SMN2
SCHEMBL2214233 0.78 DNMT1 (0.42) POLBMAPTABL1BCRABL2
SCHEMBL2215099 0.78 POLB (0.47) POLBMAPTKMT2AMEN1TDP1
SCHEMBL2214976 0.77 MAPT (0.47) POLBMAPTKMT2AMEN1LMNA
SCHEMBL2214363 0.77 HDAC1 (0.42) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2214950 0.77 PTPN1 (0.46) KMT2AMEN1PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 MPL 1851/4885POLB 828/4885MAPT 3832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.